BRAND_ANALYSIS #SANOFI HEALTH & PHARMA #24 OF 26 IN HEALTH & PHARMA ALIGNED

Sanofi

· Private · Updated 07 Aug 2026 07:45 UTC
#1007 of 1208 overall by tension · #24 of 26 in Health & Pharma
10 Aligned
The Balanced
Analysis

Big Pharma's generic consolidator. Sentiment 0.10 with C=46, B=56 reads as managed mediocrity—profitable enough to never innovate, constrained enough to never matter culturally.

IN THE NEWS (79 articles this week)
Sanofi to ‘rebuild trust’ with Regeneron; Apnimed adds to string of ‘upsized’ biotech IPOs - BioPharma Dive
Sanofi suspends chronic lung disease phase 2 study, tied to ‘strategic business reasons’ - Fierce Biotech
Sanofi pauses mid-stage lung study amid new CEO’s ‘rigorous portfolio prioritization’ - BioSpace
Cultural Score
46 / 100
Business Score
56 / 100
TREND
TENSION▁▁▁▁▁▁▁▁▁▁▁▁▁▁
CULTURAL▄▄▄▄▄▄▄▄▄▄▄▄▄▄
BUSINESS▅▅▅▄▄▅▅▄▄▄▄▄▄▄
TREND CHART
Loading...
CULTURAL BREAKDOWN
Wikipedia Momentum 15/40
News Presence 31/35
Search InterestRedistributed to other dimensions
BUSINESS BREAKDOWN
Stock Momentum 0/30
Market Position 0/25
Revenue Growth 0/25
Earnings Health 0/20
BRANDS LIKE THIS
Illumina
C:46 B:56 T:10
MyFitnessPal
C:45 B:55 T:10
Calm
C:40 B:50 T:10
Noom
C:40 B:50 T:10
Strava
C:47 B:60 T:13
SHARE
Sanofi's tension is 10. Commerce outpacing culture. sociologyofcapitalism.com/brand/sanofi
SHARE ON X
EMBED
<iframe src="https://sociologyofcapitalism.com/embed/sanofi.html" width="320" height="200" frameborder="0"></iframe>
Data: Wikipedia Pageviews, Google News RSS, AI Sentiment
All scores approximate. Updated daily.
Sociology of Capitalism
Mike Litman